semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Systemic Inflammation Cardiopulmonary-bypass Undergoing cardiac surgery with planned cardiopulmonary bypass Additive Euroscore II ≥ 3 OR at least 3 surgical cardiac interventions are planned Ability to provide informed consent (not incapacitated)  Already on renal replacement therapy Patients with chronic kidney disease defined as estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2 [ CKD stage > 3 ] Patients who are pregnant Concurrent enrollment in another clinical trial Known allergic reaction to bovine alkaline phosphatase or patient is vegetarian or vegan Patients with ongoing infections or current use of steroids
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Myofascial Trigger Points Primary headache patients with pericranial myofascial trigger points  Cranial weeks muscle infection or trauma, medical history, physical examination, laboratory and imaging studies suggest secondary headache patients except cervicalheadache
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 50.0-60.0,  Atherosclerotic Ischemic Disease Elderly patients with arteriosclerosis obliterans (Rutherford classification of class 5: slight tissue defect; class 6: tissue ulceration, gangrene) Diabetic foot, Wagnar classification of class 315: deep ulcer, often affecting bone tissue, with deep abscess or osteomyelitis Age range: 50-60 years Irrespective of gender Unilateral limb lesions Total occlusion of main blood vessels No outflow tract in distal arteries Cannot perform open surgery and endovascular surgery Signed informed consent  Moderate to severe liver and kidney dysfunction Malignant tumor Hematological system diseases Rheumatic immune system diseases Poor stimulating effect on colony stimulating factor Thromboangiitis obliterans Severe hyperthyroidism Endocrine and metabolic diseases such as severe hypothyroidism
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Low Back Pain criteriae Referral to one of the two spine centres in Central Denmark Region (Silkeborg and Aarhus) Sufficient competency in Danish to fill out questionnaires Age between 18 and 65 years, both included MRI verified type 1 Modic changes within the last 3 months, either exclusively, mixed or in combination with type 2 or type 3 changes No sign of activation of the immune system at (normal CRP) Back pain must dominate leg pain Pain duration >3 months and relevant disability (RM>5)  e On beforehand, plans of or a wish for spinal surgery Spinal surgery for disc herniation or spinal stenosis within the last 6 months Previous spinal fusion surgery Plans of treatment with antibiotics for Modic changes elsewhere Antibiotic treatment for Modic changes within the preceding ½ year More than two weeks of antibiotic treatment within the past three months Immunosuppressive treatment at present Lacking ability to enter or complete the project due to either mental, social or geographical reasons Known intestinal pathology, autoimmune disease, immune deficiency, malabsorption, cancer or chronic infection
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Osteoarthritis, Knee Male or female patients, aged between 18 and 75 years; 2. Bilateral symptomatic knee osteoarthritis (Kellgren-Lawrence grade 1-4); 3. Failure after two months of conservative treatment; 4. Capacity and consent of patients to participate actively in the rehabilitation protocol, follow-up clinic and radiology protocol; 5. Signature of informed consent  Patients incapable of discernment; 2. Patients with malignancy 3. Patients with rheumatic diseases; 4. Patients with diabetes; 5. Patients with metabolic disorders of the thyroid; 6. Patients belonging abuse of alcohol, drugs or medications; 7. Patients with misalignment of the lower limbs than 10 °; 8. Body Mass Index> 40; 9. Patients with a history of trauma or intra-articular infiltration of therapeutic substances within 6 months prior to treatment
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Peripheral Diabetic Neuropathy DM type 2 over 1 year 2. Clinical presentation of peripheral sensory such as burning pain 3. DN4 score from 4 points 4. Good consciousness to tell their score with informed consent agreement 5. No adding dosage of previous pain control medications at least 4 weeks 6. HbA1C 6.5-9.0%  Improper application site of skin for topical drugs such as abrasion wound. 2. Allergic history of Capsaicin 3. No intention to join the study with any reasons 4. Other previous medications used that effect to peripheral neuropathy such as Carboplatin, Cisplatin, Colchicine, Dapsone, Etoposide, Ethambutol, Indomethacin, Isoniazid, Lithium, Metronidazole, Phenytoin, Pyridoxine, Statins, Stavudine (d4T) or conditions worsening peripheral nerves following that poor nutrition, kidney failure, chronic alcoholism, vitamin deficiency, Hypothyroidism
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Spinal Cord Injuries Osteoporosis Metabolic Syndrome Adult (age 18-60 years) Motor complete SCI (C1-T10 AIS A/B) years post-injury Have a telephone, and ability to attend the study visits Able to take oral medications and swallow independently Can provide free and informed consent Ability to understand instructions in English May report current use of oral alendronate 10mg daily or 70mg weekly or risedronate 5mg daily, 30mg weekly or 150mg monthly  These are intended to those in whom; Rosuvastatin would be unsafe, DXA/pQCT measurement or biomarker assessment would be invalid, or in whom other co-morbid health conditions may confound the study results Current and/or one year prior to enrolment treatment with any statin such as atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, simvastatin and rosuvastatin Current treatment with IV bisphosphonate, denosumab, recombinant PTH, ovarian hormone therapy, an oral contraceptive, Immunosuppressants (Including Cyclosporine) and fusidic acid Known allergy to Rosuvastatin, lactose powder, CoQ10, calcium carbonate, vitamin D2 and vitamin D3, or any other ingredient found in rosuvastatin, placebo or study supplements History of Paget's disease, osteomalacia, steroid induced osteoporosis, or untreated parathyroid or untreated thyroid disease Subjects with history of stage 4 chronic kidney disease. (124) Current Weight ≥136 kg Bilateral knee region metal implants (hardware), history of bilateral knee region contracture >30 degrees, fracture or any other bilateral knee region pathology which would preclude accurate DXA assessment of one limb Post-menopausal women (absence of menses for a minimum of 1 year) Women with amenorrhea due to bilateral surgical removal of the ovaries and/or uterus (women with amenorrhea due to spinal cord injury are able to participate)
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Delayed Bleeding Post EMR Large Laterally Spreading Lesion in the Colon Endoscopic Mucosal Resection All patients referred for EMR of a LSL 20mm or larger Signed the informed consent  Clips used during the EMR procedure to close the defect, totally or partially Inadequate images to adequately assess the defect Use of blood thinners which have not been ceased according to the current guidelines for EMR
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 16.0-60.0,  Sickle Cell Disease Patient 1. Patients with sickle cell disease are eligible if they have any of the following complications: 1.1 Stroke or central nervous system event lasting longer than 24 hours 1.2 Frequent vaso-occlusive pain episodes, defined as ≥ 3 per year requiring emergency room, acute care center, hospital admissions, or home bedrest leading to absence from work or school. 1.3 Recurrent episodes of priapism, defined as ≥ 2 per year requiring emergency room visits 1.4 Acute chest syndrome with recurrent hospitalizations, defined as ≥ 2 lifetime events 1.5 Red-cell alloimmunization (≥ 2 antibodies) during long-term transfusion therapy 1.6 Bilateral proliferative retinopathy with major visual impairment in at least one eye 1.7 Osteonecrosis of 2 or more joints 1.8 Sickle cell nephropathy, defined by a GFR < 90mL/min/1.73m2 or the presence of macroalbuminuria (urine albumin > 300 mg/g creatinine) 1.9 Pulmonary hypertension, defined by a mean pulmonary arterypressure >25mmHg 2. Age 16-60 years 3. Karnofsky performance status of 60 or higher (Appendix A) 4. Adequate cardiac function, defined as left ventricular ejection fraction ≥ 40% 5. Adequate pulmonary function, defined as diffusion lung capacity of carbon monoxide ≥ 50% predicted (after adjustment for hemoglobin concentration) 6. Estimated GFR ≥ 50mL/min/1.73m2 as calculated by the modified MDRD equation 7. ALT ≤ 3x upper limit of normal 8. HIV-negative 9. Patient is not pregnant 10. Patient is able and willing to sign informed consent 11. Patient does not have a fully HLA-matched sibling donor 12. Patient has an HLA-haploidentical relative Donor Relatives (parents, offspring, siblings, aunts/uncles, cousins) will be tested by molecular typing of HLA class I (A, B, and C) and class II (DRB1) at low resolution. Only those that are an HLA-haploidentical match (≥ 4/8) will be considered as a potential donor. NOTE: If during testing, a fully HLA-matched sibling donor is found and is willing to donate his/her stem cells, the potential subject will not be eligible for this protocol. Donor consent will be obtained as per standard protocol of the bone marrow transplant unit
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Primary Biliary Cholangitis (PBC) Must have provided written informed consent 2. Definite or probable PBC diagnosis as demonstrated by the presence of at least 2 of the following 3 diagnostic factors History of elevated ALP levels for at least 6 months prior to Day 0 (randomization visit) Positive Anti-Mitochondrial Antibodies (AMA) titers (> 1/40 on immunofluorescence or M2 positive by enzyme-linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies Liver biopsy consistent with PBC 3. ALP >= 1.67x upper limit of normal (ULN) 4. Taking UDCA for at least 12 months (stable dose for ≥ 6 months) prior to screening visit 5. Contraception: Females participating in this study must be of non-childbearing potential or must be using highly efficient contraception for the full duration of the study and for 1 month after the end of treatment  History or presence of other concomitant liver diseases 2. Screening creatine phosphokinase (CPK) > upper limits of normal (ULN) 3. Screening alanine transaminase (ALT) or aspartate aminotransferase (AST) > 5 ULN 4. Screening total bilirubin > 2 ULN 5. Screening serum creatinine > 1.5 mg/dl 6. Significant renal disease, including nephritic syndrome, chronic kidney disease (defined as patients with markers of kidney damage or estimated glomerular filtration rate [eGFR] of less than 60 mL/min/1.73 m^2). 7. Patients with moderate or severe hepatic impairment (defined as Child-Pugh B/C) 8. Platelet count <150 X 10^3/microliter 9. Albumin <3.5 g/dL 10. Presence of clinical complications of PBC or clinically significant hepatic decompensation 11. If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating 12. Known history of human immunodeficiency virus (HIV) infection 13. Medical conditions that may cause non-hepatic increases in ALP (e.g., Paget's disease)
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Liver Fibroses Liver Cirrhoses Squamous Cell Carcinoma of the Head and Neck Patient over 18 years of age Supported in the department of Orl & CCF or Maxillo-Faciale surgery of the CHU d'Amiens Histological diagnosis of epidermoid carcinoma From the oral cavity From the oropharynx Hypopharynx Larynx Any stage of cancer Affiliation to a social security scheme  Patient already treated previously for a cancer of the VADS Patient referred to in Articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the Public Health Code
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Oedema Obesity Adults who have capacity to give informed consent Ability to understand the assessment questionnaires in English. Stage 1 all patients accepted for referral. There are no co-morbidities that would people. Stage 2 patients that undergo bariatric surgery  Patients under the lower age limit of 18. Stage 2 By-Band-Sleeve study participants who are taking part in the randomisation part of the study
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 15.0-54.0,  Pulpitis mature permanent mandibular molars having deep carious lesions involving half or more of the dentine detected by radiographic examination pulp sensibility confirmed using the electric pulp test (Digitest D626D; Parkell Electronics, New York, NY) and the cold test (Endo frost, Coltene, Whaledent) absence of apical and furcal radiolucency determined by radiographic examination absence of clinical symptoms of irreversible symptoms, fistula, swelling and abnormal tooth mobility Clinical diagnosis of vital pulp was made on the basis of radiographic and clinical examination and the pulp sensibility tests  • if they presented with signs and symptoms of irreversible pulpitis had negative response to vitality tests before or after ITR diabetic, immunocompromised pregnant had a positive history of antibiotic use in past one month or required antibiotic prophylaxis